BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)

Rhea-AI Summary

BioCryst Pharmaceuticals reported preliminary ORLADEYO® net revenue of $437 million for 2024, marking a 34% year-over-year growth. The company expects ORLADEYO revenue between $515-$535 million and total revenue of $540-$560 million in 2025.

Key highlights include achieving operating profit in 2024 (excluding stock-based compensation) and projecting quarterly EPS profitability/positive cash flow in 2H 2025. The company plans a new drug application in 2025 for ORLADEYO granules for children under 12.

Q4 2024 ORLADEYO net revenue reached $123.5 million (+36% y-o-y), with total revenue of $130.8 million (+40% y-o-y). Over 1,200 U.S. physicians have prescribed ORLADEYO across 30+ countries. The company expects 2025 GAAP operating expenses between $485-495 million, including $60 million in stock-based compensation.

Positive

• ORLADEYO revenue grew 34% y-o-y to $437M in 2024
• Q4 2024 total revenue increased 40% y-o-y to $130.8M
• Company achieved operating profit in 2024 (excluding stock-based compensation)
• Projected 20% annual revenue CAGR over next three years
• Expected to reach quarterly EPS profitability in H2 2025
• Full profitability and positive cash flow expected for 2026

Negative

• Operating expenses expected to increase to $485-495M in 2025
• Still not profitable when including stock-based compensation

Insights

Financial Analyst

BioCryst's ORLADEYO revenue surge to $437 million in 2024, marking a 34% year-over-year growth, demonstrates remarkable commercial execution. The projected 2025 revenue guidance of $515-535 million suggests continued robust growth trajectory. The company's path to profitability is particularly noteworthy - achieving operating profit in 2024 (excluding stock compensation) and targeting EPS profitability by H2 2025 indicates strong operational leverage.

The expected 20% revenue CAGR over the next three years, coupled with only 5% operating expense CAGR, points to expanding margins and improving cash flows. With over 1,200 U.S. physicians prescribing ORLADEYO and presence in 30+ countries, the $1 billion peak sales target appears achievable. The 2025 operating expense guidance of $485-495 million reflects disciplined cost management while supporting growth initiatives.

Medical Research Analyst

The planned expansion of ORLADEYO into the pediatric population (under 12 years) represents a significant market opportunity in the hereditary angioedema (HAE) space. The development of granule formulation addresses a important unmet need in young patients. Additionally, the pipeline advancement with BCX17725 for Netherton syndrome and avoralstat for diabetic macular edema shows promising portfolio diversification beyond HAE.

The accelerating prescription trends and expanding physician base validate ORLADEYO's clinical value proposition. The 34% growth in the fourth year post-launch, surpassing the previous year's 30% growth, indicates strong market penetration and physician confidence in the drug's efficacy and convenience advantages over existing treatments.

—ORLADEYO net revenue expected to be between $515-$535 million in 2025—

—Total revenue (including RAPIVAB^®) expected to be between $540-$560 million in 2025—

—Company achieved operating profit in 2024 (not including stock-based compensation) and expects to approach quarterly EPS profitability/positive cash flow in 2H 2025—

—New drug application planned in 2025 for ORLADEYO granules in children up to age 12; will address significant unmet need—

—Pipeline advancing into patients with Netherton syndrome (BCX17725) and diabetic macular edema (avoralstat) in 2025—

RESEARCH TRIANGLE PARK, N.C., Jan. 10, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced preliminary, unaudited ORLADEYO^® (berotralstat) net revenue and total revenue for the fourth quarter and full year 2024. The company also provided guidance for full year 2025 ORLADEYO net revenue and total revenue, full year 2025 operating expenses, and its expectation that the company will approach quarterly earnings per share (EPS) profitability in the second half of 2025.

“2024 was a year of outstanding execution for the company on multiple fronts and it is exciting to carry this momentum into 2025. We had another year of exceptional ORLADEYO revenue growth moving us significantly closer to peak sales of $1 billion, and we did this while driving the company toward profitability in the near-term. We are excited that this year we expect to submit a new drug application to expand the ORLADEYO label to children under age 12 and to be in patient studies in two new clinical programs (BCX17725 and avoralstat),” said Jon Stonehouse, president and chief executive officer of BioCryst.

Preliminary Fourth Quarter and Full Year 2024 ORLADEYO Revenue and Total Revenue, and 2025 ORLADEYO and Total Revenue Outlook
Preliminary, unaudited ORLADEYO net revenue in the fourth quarter of 2024 was $123.5 million (+36 percent y-o-y). Preliminary, unaudited ORLADEYO net revenue for full year 2024 was $437 million (+34 percent y-o-y).

The company expects full year 2025 global net ORLADEYO revenue will be between $515 million and $535 million.

“ORLADEYO revenue accelerated in 2024, with 34 percent annual growth in the fourth year on the market, compared to 30 percent in 2023. Over 1,200 U.S. physicians have prescribed ORLADEYO, and thousands of patients have benefitted in over 30 countries worldwide as physicians and patients continue to gain confidence in the exceptional efficacy and convenience that are possible with ORLADEYO. As we head into 2025, oral, preventative therapy with ORLADEYO is the new benchmark for HAE, and we are excited to soon bring this new option to children under age 12,” said Charlie Gayer, chief commercial officer of BioCryst.

Preliminary, unaudited total revenue in the fourth quarter of 2024 was $130.8 million (+40 percent y-o-y). Preliminary, unaudited total revenue for full year 2024 was $450 million (+36 percent y-o-y). The company expects full year 2025 total revenue (including RAPIVAB^® (peramivir injection)) will be between $540 million and $560 million.

Operating Expense Outlook
The company expects full year 2025 GAAP operating expenses to be between $485 million and $495 million. This includes an estimated $60 million related to stock-based compensation, therefore operating expenses not including stock-based compensation are forecasted at between $425 million and $435 million for the year. This operating expense outlook includes additional commercial investment to support the launch of the company’s pediatric product in HAE, ongoing work on the transition study (APeX-T), and continued generation of real-world evidence to support and enhance the company’s global commercial activities. For R&D, the additional investments include support for clinical activities for both BCX17725 and avoralstat.

Profitability Outlook
In 2024, revenue growth significantly exceeded operating expense growth. The company expects this pattern to continue, and over the next three years the company expects an annual CAGR for revenue of around 20 percent, compared to a projected annual operating expense CAGR of closer to five percent over the same period. Building on its significant operating profit in 2024 (not including stock-based compensation), the company expects to approach quarterly positive EPS and positive cash flow in the second half of 2025, and to be profitable on an EPS basis, with positive cash flow, for full year 2026.

Presentation Tuesday at 43^rd Annual J.P. Morgan Healthcare Conference
On Tuesday, January 14, 2025 at 6:00 p.m. ET, the company will present at the 43^rd Annual J.P. Morgan Healthcare Conference in San Francisco. Links to a live audio webcast and replay of the presentation may be accessed in the Investors section of BioCryst’s website at www.biocryst.com.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO^® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.

Non-GAAP Financial Measures
The information furnished in this release includes non-GAAP financial measures that differ from measures calculated in accordance with generally accepted accounting principles in the United States of America (GAAP). In particular, we provide the non-GAAP financial measure of expected full year 2025 GAAP operating expense, adjusted to show the expected results without including our estimated stock-based compensation expense.

We believe providing this non-GAAP measure, which shows our expectations with this item adjusted, is valuable and useful since it allows management and investors to better understand the company’s expected financial performance in the absence of certain non-cash items, such as stock-based compensation, and allows investors to more accurately understand our expectations and compare them to future results. This non-GAAP measure also corresponds with the way we expect Wall Street analysts to compare our results. Non-GAAP measures should be considered only as supplements to, and not as substitutes for or in isolation from, our other measures of financial information prepared in accordance with GAAP, such as GAAP revenue, operating income, net income and earnings per share.

Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding preliminary, unaudited revenue results and future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst’s actual results, performance or achievements to be materially different from any preliminary, unaudited revenue results and future results, performance or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: BioCryst’s completion of its customary closing, review and audit procedures for the fourth quarter and full year 2024, which may cause actual revenue results for these periods to differ materially from the preliminary, unaudited revenue results; BioCryst’s ability to successfully implement or maintain its commercialization plans for ORLADEYO; BioCryst’s ability to successfully progress its pipeline development plans as described herein; the results of BioCryst’s partnerships with third parties may not meet BioCryst’s current expectations; risks related to government actions, including that decisions and other actions, including as they relate to pricing, may not be taken when expected or at all, or that the outcomes of such decisions and other actions may not be in line with BioCryst’s current expectations; the commercial viability of ORLADEYO, including its ability to achieve sustained market acceptance and demand; ongoing and future preclinical and clinical development of product candidates may take longer than expected and may not have positive results; BioCryst may not be able to enroll the required number of subjects in planned clinical trials of product candidates; BioCryst may not advance human clinical trials with product candidates as expected; the FDA or other applicable regulatory agency may require additional studies beyond the studies planned for products and product candidates, may not provide regulatory clearances which may result in delay of planned clinical trials, may impose certain restrictions, warnings, or other requirements on products and product candidates, may impose a clinical hold with respect to product candidates, or may withhold, delay or withdraw market approval for products and product candidates; product candidates, if approved, may not achieve market acceptance; BioCryst’s ability to successfully commercialize its products and product candidates; BioCryst’s ability to successfully manage its growth and compete effectively; risks related to the international expansion of BioCryst’s business; timing for achieving and sustainability of profitability and positive cash flow may not meet management’s expectations; statements and projections regarding financial guidance and goals and the attainment of such goals may differ from actual results based on market factors and BioCryst’s ability to execute its operational and budget plans; and actual financial results may not be consistent with expectations, including that revenue, operating expenses and cash usage may not be within management’s expected ranges. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which identify important factors that could cause actual results to differ materially from those contained in BioCryst’s projections and forward-looking statements.

BCRXW

Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com

FAQ

What is BCRX's projected ORLADEYO revenue for 2025?

BioCryst projects ORLADEYO net revenue to be between $515-535 million for 2025.

How much did ORLADEYO sales grow in Q4 2024 for BCRX?

ORLADEYO net revenue grew 36% year-over-year to $123.5 million in Q4 2024.

When does BCRX expect to achieve quarterly EPS profitability?

BioCryst expects to approach quarterly EPS profitability in the second half of 2025.

What are BCRX's expected operating expenses for 2025?

BioCryst expects GAAP operating expenses between $485-495 million for 2025, including $60 million in stock-based compensation.

How many physicians have prescribed ORLADEYO for BCRX?

Over 1,200 U.S. physicians have prescribed ORLADEYO across more than 30 countries worldwide.